The End Of Small Molecule Drugs? Potential Implications Of US Price ‘Negotiation’

The drug pricing provisions in the Build Back Better bill include a number of exemptions and protections – each of which could have interesting consequences for pharmaceutical development.

Sinking prescriptions
Will Build Back Better sink small molecule drugs? • Source: Nielsen Hobbs; the Pink Sheet |Alamy images

This could be the year that the US Medicare program gains the authority to negotiate prescription drug prices after all.

An eleventh-hour compromise approach among Congressional Democrats is now moving forward. The good news for manufacturers is that the new...

More from Pricing Debate

More from Market Access